We are one of the sites currently conducting a clinical trial with Regeneron to better understand the efficacy of REGN-COV2 in treating mild to moderate cases of Covid-19. It has already been approved by the FDA for emergency use and is one of the drugs that Mr. Trump received. This study is in Phase III of research and we are actively enrolling eligible participants.
- We are looking for patients that tested positive for COVID-19 in the past 3-7 days.
- The compensation for participation is $3,650 (participants receive half at day 15 of treatment and the rest at day 30).
Email us with questions at email@example.comCheck Eligibility
San Francisco Research Institute understands your need to move your product through the development pipeline expediently. The Phase I – IV clinical trials done at our institute are completed in a timely manner. We work closely with sponsors and CROs to insure the best quality of clinical research.